telmisartan has been researched along with Cancer of Esophagus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiyo, T; Fujihara, S; Fujita, K; Iwama, H; Kobara, H; Kobayashi, N; Masaki, T; Matsui, T; Morishita, A; Nakahara, M; Namima, D; Nishiyama, N; Yachida, T | 1 |
| Chiyo, T; Fujihara, S; Iwama, H; Kato, K; Kobara, H; Masaki, T; Mori, H; Morishita, A; Ogawa, K; Tadokoro, T | 1 |
2 other study(ies) available for telmisartan and Cancer of Esophagus
| Article | Year |
|---|---|
Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin A2; Cyclin-Dependent Kinase 2; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Receptor, ErbB-3; S Phase; Telmisartan; Thrombospondin 1 | 2019 |
The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Benzimidazoles; Benzoates; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Phosphorylation; Receptor, ErbB-2; Signal Transduction; Telmisartan; Time Factors; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |